FAQ on Izotropic Corp.'s Next-Gen Breast Cancer Imaging Technology

What is the IzoView Breast CT Imaging System?

The IzoView Breast CT Imaging System is a contrast-enhanced CT platform designed by Izotropic Corp. to enhance the precision of breast cancer screening, particularly benefiting women with dense breast tissue where traditional mammography is less effective.

Why is the IzoView system significant?

It addresses critical gaps in breast cancer detection, offering a more accurate diagnostic tool for women with dense breast tissue, a group for whom mammography often falls short.

How does the IzoView system work?

While the content does not detail the technical workings, the IzoView system is described as a contrast-enhanced CT platform designed for enhanced screening precision in breast cancer detection.

Who is behind the development of the IzoView system?

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is the company developing the IzoView Breast CT Imaging System.

When is the IzoView system expected to be available?

Izotropic is actively preparing for the commercialization of IzoView, though the content does not specify an exact timeline.

Where will the IzoView system be applicable?

The system is designed to improve breast cancer screening, particularly in the U.S., where breast cancer is the most commonly diagnosed cancer among women, excluding nonmelanoma skin cancer.

What are the benefits of the IzoView system?

The primary benefit is its enhanced precision in detecting breast cancer, especially in women with dense breast tissue, where traditional mammography is less effective.

How can I stay updated on Izotropic Corp.’s developments?

Updates relating to Izotropic Corp. (IZOZF) are available in the company’s newsroom at ibn.fm/IZOZF.

What is the current status of breast cancer in the U.S.?

Breast cancer is the most diagnosed cancer among U.S. women (excluding nonmelanoma skin cancer), with approximately 316,950 new cases of invasive breast cancer expected in women in 2025.